Profile data is unavailable for this security.
About the company
Neovacs SA is a France-based company active in the biotechnology industry. It specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The Company researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The Company focuses its development effort on two Kinoids for Crohn’s disease, Rheumatoid Arthritis and lupus disease. Neovacs SA’s portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The Company operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.
- Revenue in EUR (TTM)53.48k
- Net income in EUR-5.00m
- Incorporated1992
- Employees23.00
- LocationNeovacs SA3-5, Impasse ReillePARIS 75014FranceFRA
- Phone+33 153109300
- Fax+33 153109303
- Websitehttps://www.neovacs.com/fr/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharnext SCA | 150.00k | -31.55m | 90.88k | 44.00 | -- | -- | -- | 0.6059 | -26,278,830.00 | -26,278,830.00 | 171.43 | -17,532.99 | 0.0186 | -- | 0.0298 | -- | -391.03 | -128.26 | -- | -367.63 | -22.54 | -- | -21,035.67 | -4,413.23 | -- | -- | -- | -- | -99.34 | -- | -25.57 | -- | -29.58 | -- |
| Neovacs SA | 53.48k | -5.00m | 101.99k | 23.00 | 0.00 | 0.00 | -- | 1.91 | 14,869,250.00 | 14,869,250.00 | 764.00 | 364,547.30 | 0.001 | -- | 0.5561 | 2,546.67 | -9.24 | -36.05 | -10.24 | -46.06 | -917.26 | -3,215.82 | -9,344.13 | -74,596.98 | -- | -- | 0.0286 | -- | -95.08 | -- | 70.02 | -- | 3.58 | -- |
| Paion AG | -100.00bn | -100.00bn | 214.01k | 64.00 | -- | -- | -- | -- | -- | -- | -- | -0.4074 | -- | -- | -- | -- | -- | -24.86 | -- | -34.32 | -- | -- | -- | -52.40 | 0.5078 | -- | 1.17 | -- | 366.42 | 41.74 | 97.34 | -- | 129.37 | -- |
| XP Chemistries AB | 56.82k | -688.18k | 303.91k | 2.00 | -- | 0.1382 | -- | 5.35 | -0.2846 | -0.2846 | 0.0213 | 0.275 | 0.023 | 0.2084 | 5.99 | 331,845.00 | -27.79 | -- | -29.36 | -- | 50.57 | -- | -1,211.24 | -- | 5.79 | -- | 0.00 | -- | -37.14 | -- | -1.55 | -- | -- | -- |
| QuiaPEG Pharmaceuticals Holding AB | 0.00 | -1.41m | 464.93k | 8.00 | -- | 0.3561 | -- | -- | -3.51 | -3.51 | 0.00 | 0.2047 | 0.00 | -- | -- | -- | -50.53 | -95.67 | -100.54 | -207.86 | -- | 262.59 | -- | -5,002.50 | -- | -15.34 | 0.00 | -- | -- | -- | 17.75 | -- | 47.06 | -- |
| MediNavi AG | -100.00bn | -100.00bn | 484.93k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
